Deafness Reversed: Single Injection Brings Hearing Back Within Weeks

Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results

Gene therapy is a promising approach for hereditary deafness. We recently showed that unilateral AAV1-hOTOF gene therapy with dual adeno-associated virus (AAV) serotype 1 carrying human OTOF transgene is safe and associated with functional improvements in patients with autosomal recessive deafness 9 (DFNB9). The protocol was subsequently amended and approved to allow bilateral gene therapy administration. Here we report an interim analysis of th…

Breakthrough gene therapy jab reverses hearing loss in weeks

Researcher says this type of treatment for deafness is ‘just the beginning’

Gene Therapy Can Restore Hearing in Adults, First-of-Its-Kind Trial Shows

Up to three in every 1,000 newborns has hearing loss in one or both ears.

Deafness reversed: Single injection brings hearing back within weeks

A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost f…

Gene therapy restored hearing in deaf patients - Scientific Inquirer

Gene therapy can improve hearing in children and adults with congenital deafness or severe hearing impairment, a new study involving researchers at Karolinska Institutet reports. Hearing improved in all ten patients, and the treatment was well-tolerated. The study was conducted in collaboration with hospitals and universities in China and is published in the journal Nature Medicine. “This is a huge step forward in the genetic treatment of deafne…

Sensorion Reports Positive Preliminary Data for Pediatric Hearing Loss Gene Therapy Trial | Hearing Health & Technology Matters

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies to treat and prevent hearing loss disorders, has announced encouraging preliminary data from the first patient cohort of its ongoing Phase 1/2 Audiogene clinical trial. The trial evaluates SENS-501, an investigational gene therapy candidate targeting a specific form of congenital deafness caused by mutations in the…